Annual SGA
$6.73 M
+$514.80 K+8.28%
December 31, 2023
Summary
- As of February 7, 2025, IKT annual SGA is $6.73 million, with the most recent change of +$514.80 thousand (+8.28%) on December 31, 2023.
- During the last 3 years, IKT annual SGA has risen by +$4.11 million (+156.63%).
- IKT annual SGA is now at all-time high.
Performance
IKT SGA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly SGA
$1.64 M
-$337.10 K-17.07%
September 30, 2024
Summary
- As of February 7, 2025, IKT quarterly SGA is $1.64 million, with the most recent change of -$337.10 thousand (-17.07%) on September 30, 2024.
- Over the past year, IKT quarterly SGA has dropped by -$337.10 thousand (-17.07%).
- IKT quarterly SGA is now -19.39% below its all-time high of $2.03 million, reached on June 30, 2019.
Performance
IKT Quarterly SGA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM SGA
-$297.25 M
-$19.57 M-7.05%
September 30, 2024
Summary
- As of February 7, 2025, IKT TTM SGA is -$297.25 million, with the most recent change of -$19.57 million (-7.05%) on September 30, 2024.
- Over the past year, IKT TTM SGA has dropped by -$304.28 million (-4328.72%).
- IKT TTM SGA is now -2339.73% below its all-time high of -$12.18 million.
Performance
IKT TTM SGA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Selling, General & Administrative Expenses Formula
SGA = Total Operating Expenses - Cost of Goods Sold - Research & Development
IKT Selling, General & Administrative Expenses Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +8.3% | -17.1% | -4328.7% |
| 3 y3 years | +156.6% | -14.9% | -4692.3% |
| 5 y5 years | +167.6% | -14.9% | -4692.3% |
IKT Selling, General & Administrative Expenses Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +8.3% | -19.4% | +21.8% | -221.1% | at low |
| 5 y | 5-year | at high | +156.6% | -19.4% | +342.2% | -2339.7% | at low |
| alltime | all time | at high | +167.6% | -19.4% | +342.2% | -2339.7% | at low |
Inhibikase Therapeutics Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | $1.64 M(-17.1%) | $7.04 M(+0.2%) |
| Jun 2024 | - | $1.97 M(-2.8%) | $7.03 M(+2.8%) |
| Mar 2024 | - | $2.03 M(+45.0%) | $6.84 M(+1.6%) |
| Dec 2023 | $6.73 M(+8.3%) | $1.40 M(-13.7%) | $6.73 M(+0.8%) |
| Sep 2023 | - | $1.62 M(-9.0%) | $6.68 M(+1.3%) |
| Jun 2023 | - | $1.78 M(-7.4%) | $6.59 M(+1.8%) |
| Mar 2023 | - | $1.93 M(+43.2%) | $6.47 M(+4.1%) |
| Dec 2022 | $6.22 M(-4.5%) | $1.34 M(-12.6%) | $6.22 M(-4.7%) |
| Sep 2022 | - | $1.54 M(-7.5%) | $6.53 M(-1.6%) |
| Jun 2022 | - | $1.66 M(-0.3%) | $6.63 M(+0.8%) |
| Mar 2022 | - | $1.67 M(+1.0%) | $6.58 M(+1.1%) |
| Dec 2021 | $6.51 M | $1.65 M(+0.5%) | $6.51 M(+8.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2021 | - | $1.64 M(+2.2%) | $6.00 M(+21.6%) |
| Jun 2021 | - | $1.61 M(+0.5%) | $4.93 M(+33.5%) |
| Mar 2021 | - | $1.60 M(+39.9%) | $3.70 M(+40.9%) |
| Dec 2020 | $2.62 M(-38.5%) | $1.14 M(+97.0%) | $2.62 M(+40.0%) |
| Sep 2020 | - | $580.80 K(+56.8%) | $1.87 M(-20.8%) |
| Jun 2020 | - | $370.30 K(-29.8%) | $2.37 M(-41.2%) |
| Mar 2020 | - | $527.70 K(+33.7%) | $4.03 M(-5.6%) |
| Dec 2019 | $4.27 M(+69.6%) | $394.60 K(-63.3%) | $4.27 M(+10.2%) |
| Sep 2019 | - | $1.07 M(-47.1%) | $3.87 M(+38.4%) |
| Jun 2019 | - | $2.03 M(+164.5%) | $2.80 M(+264.5%) |
| Mar 2019 | - | $768.00 K | $768.00 K |
| Dec 2018 | $2.52 M | - | - |
FAQ
- What is Inhibikase Therapeutics annual SGA?
- What is the all time high annual SGA for Inhibikase Therapeutics?
- What is Inhibikase Therapeutics annual SGA year-on-year change?
- What is Inhibikase Therapeutics quarterly SGA?
- What is the all time high quarterly SGA for Inhibikase Therapeutics?
- What is Inhibikase Therapeutics quarterly SGA year-on-year change?
- What is Inhibikase Therapeutics TTM SGA?
- What is the all time high TTM SGA for Inhibikase Therapeutics?
- What is Inhibikase Therapeutics TTM SGA year-on-year change?
What is Inhibikase Therapeutics annual SGA?
The current annual SGA of IKT is $6.73 M
What is the all time high annual SGA for Inhibikase Therapeutics?
Inhibikase Therapeutics all-time high annual SGA is $6.73 M
What is Inhibikase Therapeutics annual SGA year-on-year change?
Over the past year, IKT annual SGA has changed by +$514.80 K (+8.28%)
What is Inhibikase Therapeutics quarterly SGA?
The current quarterly SGA of IKT is $1.64 M
What is the all time high quarterly SGA for Inhibikase Therapeutics?
Inhibikase Therapeutics all-time high quarterly SGA is $2.03 M
What is Inhibikase Therapeutics quarterly SGA year-on-year change?
Over the past year, IKT quarterly SGA has changed by -$337.10 K (-17.07%)
What is Inhibikase Therapeutics TTM SGA?
The current TTM SGA of IKT is -$297.25 M
What is the all time high TTM SGA for Inhibikase Therapeutics?
Inhibikase Therapeutics all-time high TTM SGA is -$12.18 M
What is Inhibikase Therapeutics TTM SGA year-on-year change?
Over the past year, IKT TTM SGA has changed by -$304.28 M (-4328.72%)